Cancer vaccines (Q74539555)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9585204%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

review article

1 reference

title

Cancer vaccines (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9585204%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

D M Pardoll

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9585204%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

publication date

1 May 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9585204%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9585204%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9585204%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

issue

5 Suppl

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9585204%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

page(s)

525-531

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9585204%20AND%20SRC:MED&resulttype=core&format=json

Mechanisms of syngeneic tumor rejection. Susceptibility of host-selected progressor variants to various immunological effector cells

11 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Multiple tumour-specific antigens expressed on a single tumour cell

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Abrogation of metastatic properties of tumour cells by de novo expression of H–2K antigens following H–2 gene transfection

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Antigenic specificities on murine sarcoma cells. Reciprocal relationship between normal transplantation antigens (H-2) and tumor-specific immunogenicity

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Extrathymic acquisition of tolerance by T lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

T-cell tolerance by clonal anergy in transgenic mice with nonlymphoid expression of MHC class II I–E

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Induction of antigen-specific T cell anergy: An early event in the course of tumor progression

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Antigenic Cancer Cells Grow Progressively in Immune Hosts without Evidence for T Cell Exhaustion or Systemic Anergy

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Self Antigens Expressed by Solid Tumors Do Not Efficiently Stimulate Naive or Activated T Cells: Implications for Immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Induction of anti-self-immunity to cure cancer

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4.

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Tumor immunotherapy: the tumor cell as an antigen-presenting cell

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Murine interleukin-4 displays potent anti-tumor activity in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Stabilization of beta-catenin by genetic defects in melanoma cell lines

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Genes Coding for Tumor Antigens Recognized by Cytolytic T Lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Human tumor antigens recognized by T cells

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines.

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Molecular themes in oncogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Cooperation between oncogenes

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Mutations in the p53 gene occur in diverse human tumour types

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes.

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Oncogenic proteins as tumor antigens

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Prevention of breast tumour development in vivo by downregulation of the p185neureceptor

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

A novel type of human papillomavirus associated with genital neoplasias

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Serological response of melanoma patients to vaccines prepared from VSV lysates of autologous and allogeneic cultured melanoma cells

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Viral oncolysis: increased immunogenicity of host cell antigen associated with influenza virus

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Immunotherapy of malignancy by in vivo gene transfer into tumors

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Paracrine cytokine adjuvants in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Dendritic cells and the control of immunity

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Peptide-induced antiviral protection by cytotoxic T cells

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

T cell priming versus T cell tolerance induced by synthetic peptides

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Live recombinant vaccinia virus protects chimpanzees against hepatitis B.

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Tumour prevention and rejection with recombinant vaccinia.

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier.

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Protective immunity evoked by oral administration of attenuated aroA Salmonella typhimurium expressing cloned streptococcal M protein

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

New use of BCG for recombinant vaccines

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Humoral and cell-mediated immune responses to live recombinant BCG–HIV vaccines

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Delivery of a viral antigen to the class I processing and presentation pathway by Listeria monocytogenes.

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

The interaction of bacteria with mammalian cells

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Innate immunity to a facultative intracellular bacterial pathogen

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Heterologous and homologous protection against influenza A by DNA vaccination: optimization of DNA vectors.

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Exposing the immunology of naked DNA vaccines

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Priming of Cytotoxic T Lymphocytes by DNA Vaccines: Requirement for Professional Antigen Presenting Cells and Evidence for Antigen Transfer from Myocytes

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Immunostimulatory DNA sequences necessary for effective intradermal gene immunization

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Bacterial DNA-Induced NK Cell IFN-γ Production Is Dependent on Macrophage Secretion of IL-12

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Dendritic Cells Retrovirally Transduced with a Model Antigen Gene Are Therapeutically Effective against Established Pulmonary Metastases

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Dendritic Cells Genetically Modified with an Adenovirus Vector Encoding the cDNA for a Model Antigen Induce Protective and Therapeutic Antitumor Immunity

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Cellular requirements for tumor-specific immunity elicited by heat shock proteins: tumor rejection antigen gp96 primes CD8+ T cells in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

The endoplasmic reticulum-resident stress protein gp96 binds peptides translocated by TAP.

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Immunotherapy of Tumors with Autologous Tumor-Derived Heat Shock Protein Preparations

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Efficiency of MHC class I antigen processing: a quantitative analysis

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Enhancement of antitumor immunity by CTLA-4 blockade

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-525

7 January 2021

Identifiers

DOI

10.1038/NM0598SUPP-525

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9585204%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9585204%20AND%20SRC:MED&resulttype=core&format=json